- Net income reached $14.2M vs. net loss of $7.3M in Q3 2025, driven by Takeda licensing revenue recognition.
- Diluted EPS came in at $0.70; cash and cash equivalents totaled $259.5M as of September 30, 2026.
- Management expects cash runway to extend into the second half of 2028.
Why is $KROS moving today? · SEC 8-K archive
$KROS SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $KROS: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $KROS filing catalyst
Why did $KROS trigger an AI stock catalyst alert?
$KROS triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +4.5/10). Headline: Keros Therapeutics Reports Q3 2026 Net Income of $14.2M Driven by Takeda License. Key points: - Net income reached $14.2M vs. net loss of $7.3M in Q3 2025, driven by Takeda licensing revenue recognition. - Diluted EPS came in at $0.70; cash and cash equivalents totaled $259.5M as of September 30, 2026. - Management expects cash runway to extend into the second half of 2028.
How did $KROS stock react after the SEC filing?
After the SEC 8-K for $KROS, observed market reaction: T0 price $9.45. Past moves do not guarantee future results.
Where can I get real-time $KROS SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $KROS via Telegram and the VIP Web Terminal from €10/month.